Medpage Today on MSN5d
Hitting Psoriatic Arthritis Early With Apremilast Helps Some Patients, Trial Finds
With more than 300 patients in the trial, dubbed FOREMOST, 33.9% of those assigned to apremilast achieved minimal disease ...
Daily1d
FOREMOST Trial Reveals Apremilast Enhances Disease Control in Early Oligoarticular Psoriatic Arthritis
USA: The results of the FOREMOST trial indicate that apremilast is effective for patients with early psoriatic arthritis (PsA ...
BMJ2d
Guselkumab in Behçet’s disease
The mucocutaneous and articular clinical phenotype is the most common presentation of Behçet’s disease (BD).1 Current ...
Westside Current on MSN20h
TEPEZZA® (TEPROTUMUMAB) RECEIVES APPROVAL IN JAPAN FOR THE TREATMENT OF ACTIVE THYROID EYE DISEASE
Amgen (NASDAQ:AMGN) today announced TEPEZZA® (JAN: Teprotumumab (Genetical Recombination)) has been approved for the ...
stocknews22h
3 Biotech Stocks That Could Deliver Big Gains
The biotech industry is poised for significant growth, fueled by advanced technologies, the increased commercialization of ...
rheumatologyadvisor7d
Deucravacitinib for Plaque Psoriasis Shows Improved Patient-Reported Outcomes
Improvements in 2 patient-reported outcome measures were observed among patients with psoriasis treated with deucravacitinib vs placebo or apremilast.
Morningstar12d
AMGEN TO PRESENT DATA FROM MULTIPLE EARLY-STAGE CLINICAL TRIALS AT ESMO 2024
Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla® (apremilast) (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), our acquisitions of Teneobio ...
Stockhouse12d
AMGEN TO PRESENT DATA FROM MULTIPLE EARLY-STAGE CLINICAL TRIALS AT ESMO 2024
(apremilast) (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), our acquisitions of Teneobio, Inc., ChemoCentryx, Inc., or Horizon Therapeutics plc (including the ...